In this regard, liraglutide (RR 0.5474 [95% CI 0.0350, 8.5718
Beyond their established role in T2D, GLP-1RAs are under investigation for potential therapeutic applications in additional clinical domains: non-alcoholic fatty liver disease (NAFLD) [22], neurodegenerative conditions [23], and addiction reduction(including smoking, alcohol use disorder, and cocaine use disorder, putatively via mechanisms analogous to those underlying appetite suppression) [23]
Advertisement If you have obesity or Type 2 diabetes, your healthcare provider may recommend blood and imaging tests to screen for signs of this condition
Retatrutide has not received MHRA marketing authorisation and is not available through the NHS or private prescribing in the UK
Because these compounds mimic or change normal signalling, they usually function with your biology instead of against it